Australia's most trusted
source of pharma news
Friday, 10 April 2026
Posted 10 April 2026 PM
Eli Lilly's oral obesity treatment has been approved by the FDA three months after Novo Nordisk's Wegovy pill, setting up a head-to-head battle for marketshare.
And for the first time Lilly has revealed the pill's trade name and price point.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.